Background. Because activation of T cells is associated with human immunodeficiency virus (HIV) pathogenesis, CD4 and CD8 activation levels in patients coinfected with HIV and hepatitis C virus (HCV) may explain conflicting reports regarding effects of HCV on HIV disease progression.
Background. Because activation of T cells is associated with human immunodeficiency virus (HIV) pathogenesis, CD4 and CD8 activation levels in patients coinfected with HIV and hepatitis C virus (HCV) may explain conflicting reports regarding effects of HCV on HIV disease progression.
Methods. Kaplan-Meier and multivariate Cox regression models were used to study the risk of incident clinical AIDS and AIDS-related deaths among 813 HCV-negative women with HIV infection, 87 HCV-positive nonviremic women with HIV coinfection, and 407 HCV-positive viremic women with HIV coinfection (median follow-up time, 5.2 years). For 592 women, the percentages of activated CD4 and CD8 T cells expressing HLA-DR (DR) and/or CD38 were evaluated.
Results. HCV-positive viremic women had a statistically significantly higher percentage of activated CD8 T cells ( ) and a statistically significantly higher incidence of AIDS compared with HCV-negative women P ! Ϫ DR Ϫ T cells were associated with a 160% decreased risk of AIDS for HCV-positive viremic women and HCV-negative women.
Conclusion. HCV-positive viremic women with HIV coinfection who have high levels of T cell activation may have increased risk of AIDS. Earlier treatment of HIV and HCV infection may be beneficial.
Persistent generalized immune activation is a hallmark of human immunodeficiency virus (HIV) infection and is associated with CD4 cell count and HIV RNA level [1] [2] [3] [4] [5] [6] [7] . Activation of T cells accelerates their maturation and is associated with decreased CD4 level, increased of the effect of HCV on HIV disease progression have been conflicting [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In contrast, all studies find liver disease to be accelerated in HIV-coinfected patients compared with patients singly infected with HCV [20] [21] [22] . Determining the association between HCV and HIV is critical for clinical management of both infections in coinfected patients. We assessed the effect of HIV and HCV on HIV disease progression in a prospective cohort of women, and we determined the percentages of CD4 and CD8 T cells that expressed the cell surface markers HLA-DR (DR) and/or CD38 as measures of immune activation. We hypothesized that the combined effects of these 2 viruses would be increased immune activation and higher likelihood of HIV disease progression.
METHODS

Study design.
The methods and baseline cohort characteristics of the Women's Interagency HIV Study have been described elsewhere [23] . Women were enrolled during 1994-1995 or 2001-2002 at 6 sites in the United States. Only women enrolled during 1994-1995 were included in this study. Approval from the local institutional review boards was obtained, as was informed consent from all study participants. Clinical and laboratory evaluations, including CD4 cell counts, HIV RNA levels, and platelet counts, were performed at 6-month intervals, and aspartate and alanine aminotransferase levels were determined every 6-12 months. Among 1365 HIV-positive women who had not experienced an AIDS-defining clinical condition at or before study entry, baseline HCV seropositivity and HCV RNA status were available for 1307 women ( Figure  1) . Through September 2004, the median follow-up time was 5.2 years (range, 0.35-9.9 years) with 14,420 person-years of observation. Immune activation marker data from 3 published substudies were pooled (1972 evaluations; median, 3 measures/ person) [7, 24, 25] (Figure 2) . Laboratory evaluations. HIV RNA levels were determined using isothermal nucleic acid sequence-based amplification (Organon Teknika) in laboratories certified by the National Institute of Allergy and Infectious Diseases. Baseline HCV antibody testing was performed using enzyme immunoassays (version 2.0 or 3.0; Abbott). HCV RNA levels were measured in a single laboratory (principal investigator: A. Kovacs) by means of polymerase chain reaction (Roche Diagnostics) as described elsewhere [26] . For 260 HCV-positive viremic women, HCV genotype was determined using the NC Trugene HCV 5 NC genotyping kit (Bayer HealthCare). The AIDS Clinical Trials Group (ACTG) Consensus Protocol was used for 3-color flow cytometry in laboratories certified by the National Institute of Allergy and Infectious Diseases [27] (FACSCalibur; Becton Dickinson) by means of the following fluorochromeconjugated antibodies: anti-CD3, anti-CD4, anti-CD8, anti-HLA-DR, and anti-CD38 (Becton Dickinson or PharMingen) as reported elsewhere [7, 24, 25] .
Clinical outcomes. The first self-reported AIDS-defining clinical condition or AIDS-related death (if death was the first event), excluding CD4 cell count criteria, defined AIDS onset [28, 29] . Death certificates were requested for women who died, as reported elsewhere [28] . The date of AIDS onset was imputed as the midpoint between the date of the visit at which an AIDSdefining condition was reported (or the date of AIDS-related death) and the date of the previous visit [28] . AIDS-free survival was defined as the time between the date of enrollment in the Women's Interagency HIV Study and the date of the earliest occurrence of an AIDS-defining condition, the date of AIDSrelated death, the date of death not due to AIDS, or the date of the last visit at which the patient was AIDS free (through September 2004).
Parameterization of T cell data. HIV RNA level was evaluated as a time-dependent variable. CD4 cell count was modeled as a time-dependent categorical variable with respect to a value of !200 cells/mL at any time during the follow-up period: never !200 cells/mL, !200 cells/mL only previously, !200 cells/ mL only currently, or !200 cells/mL previously and currently. This parameterization of CD4 cell count showed a stronger association with AIDS risk than did CD4 cell count categorized at each visit as !200 cells/mL vs 200-350, 351-500, or 1500 cells/mL (data not shown). Percentages of CD4 and CD8 T lymphocytes that expressed HLA-DR and/or CD38 were categorized using tertiles and modeled as time-dependent variables.
Other model covariates. Race/ethnicity, baseline HCV serology, and HCV RNA level were modeled as fixed variables. Women were categorized as HCV-negative, HCV-positive nonviremic, or HCV-positive viremic by quartiles (HCV RNA level: р983,000, 983,001-2,395,000, 2,395,001-3,980,000, or 13,980,000 IU/mL). Other time-dependent factors included antiretroviral therapy (ART), age, smoking, alcohol use, injection drug use, and antibiotic prophylaxis. The aspartate to platelet ratio index, a marker of liver fibrosis [30] , was assessed as a time-dependent covariate.
Statistical analysis. SAS software (version 9.1; SAS Institute) was used for the statistical analyses. Demographic characteristics, clinical characteristics, and AIDS outcomes were compared between HCV-negative, HCV-positive nonviremic, and HCV-positive viremic women by use of x 2 tests for categorical variables and Wilcoxon rank sum tests for continuous variables. Kaplan-Meier analyses were used to estimate the unadjusted probability of remaining AIDS-free or of remaining alive by HCV status. Cox proportional hazards models were used to evaluate the relationship between the onset of an AIDSdefining condition (or AIDS-related death if first event) and exposures of interest with hazard ratios (HRs) and 95% confidence intervals (CIs). AIDS diagnosis was analyzed as a single outcome adjusted for age, race, and HCV status. Other model covariates were included if they were statistically significantly associated with AIDS or if they altered the HR for the exposures of interest by 110%. AIDS risk at a given event time was associated with exposures measured at the preceding 6-month visit. If these data were missing, we used data from the preceding 1-year visit; we did not carry forward exposure data beyond 1 year. To evaluate the effect of HCV status on AIDS in ART-naive women, separate analyses were conducted with censoring at ART initiation.
Correlates of CD4 and CD8 activation were determined using generalized estimating equations that accounted for withinsubject correlation of the measures taken over time. An exchangeable correlation matrix was assumed between any 2 measures of a given subject. Mean percentages of CD4 and CD8 cells expressing CD38 and/or HLA-DR over time were reported for the categories of each independent variable. Correlates of baseline HCV status were determined using x 2 tests. Factors related to both T cell activation and HCV status were included in multivariate generalized estimating equation models in which T cell activation markers were the outcomes of interest and HCV status was the primary exposure of interest. Risk of AIDS by tertiles of CD4 and CD8 activation markers was evaluated using Cox proportional hazards models adjusted for age, race, ART, smoking, and HCV RNA level as defined above (hereafter model 1). Additional models tested for the effect of either HIV RNA level or CD4 cell count (or both). Stratified analyses were also conducted for HCV-negative and HCV-positive viremic women. Separate Cox regression analyses evaluated whether HR estimates for immune activation markers varied between fresh samples or frozen samples (data not shown). Because there were no substantial differences, data were pooled in our final models.
RESULTS
Demographic and baseline clinical characteristics of study participants. Among the 1307 women included in the study, there were 813 HCV-negative women (62%), 87 HCV-positive nonviremic women (7%), and 407 HCV-positive viremic women (31%). Among the 260 HCV-positive viremic women for whom HCV genotype was determined, 210 (80%) were infected with genotype 1. HCV-positive women were older and more likely to be injection drug users than HCV-negative women ( Table 1) . Number of sexual partners and CD4 and CD8 cell counts were similar among the groups. The overall prevalence of injection drug use during the follow-up period was 0.4% (range, 0%-1%) in HCV-negative women, 10.5% (range, 0%-21%) in HCV-positive nonviremic women, and 12.7% (range, 6%-26%) in HCV-positive viremic women ( [ x 2 test]; data not shown). Although anti-HCV ther-P ! .001 apy was not generally given during the period of this study, 19 of 1307 women received interferon, the majority after the 10th visit. Among these 19 women, there were 14 HCV-positive viremic women, 1 HCV-positive nonviremic woman, and 4 HCV-negative women. None of these women received ribavirin.
The 592 women with immune activation data were slightly older (mean age, 37.4 vs 35.5 years); were more likely African American or Hispanic (82.5% vs 77.5%), injection drug users (53% vs 27%), and smokers (58% vs 49%); and had higher CD4 cell counts (mean, 439 vs 403 cells/mL) and CD8 cell counts (mean, 964 vs 867 cells/mL) than women without these data (data not shown).
Disease progression and HCV. Among the 1307 women who were AIDS free at baseline, 495 developed AIDS, including 162 women who died an AIDS-related death during 10 years of follow-up. Although at the time of first AIDS diagnosis there were no statistically significant differences in reported individual AIDS-defining conditions between HCV-negative women and HCV-positive women, by the end of follow-up HCV-positive viremic women were more likely to have bacterial pneumonia (20% vs 13%;
), dementia and/or encephalop-P p .002 athy (11% vs 7%; ), and wasting syndrome (12% vs P p .02 8%;
) than were HCV-negative women. By the end of P p .03 follow-up, HCV-positive viremic women were also more likely to have tuberculosis than were HCV-negative women; however, the difference was borderline statistically significant (6% vs 4%;
). HCV-positive viremic women were less likely to have P p .06 any cancer (5% vs 8%;
) and toxoplasmosis (0.6% vs P p .03 2%;
) than were HCV-negative women. P p .03 Kaplan-Meier analyses showed that HCV-positive viremic women were more likely to develop AIDS with an HCV RNA level of 12.3 million IU/mL ( Figure 3A ) and were more likely to die an AIDS-related death with an HCV RNA level of 13.98 million IU/mL ( Figure 3B ) than were women in the other groups ( and , respectively [log-rank test]). P ! .001 P p .03 Among women who never had a CD4 cell count of !200 cells/ mL, HCV-positive women (regardless of HCV RNA status) were more likely to develop AIDS than were HCV-negative women ( Figure 3C ), with rates at 1, 3, and 5 years after study entry of 13% vs 7%, 26% vs 16%, and 33% vs 21%, respectively (P ! ). .001
After adjusting for age, race, smoking, and ART, we found HCV status, injection drug use, CD4 cell count, and HIV plasma RNA level to be independent risk factors for AIDSdefining conditions in the Cox model ( + DR + T cells, there was no statistically significant positive trend overall by HCV status. However, after the HCV-negative group was removed from the analysis, the trend was statistically significant among HCV-positive women ( ). P p .02 (2) 5 (1) No. of sexual partners 0 9 (1) 1 (1) 6 (1) 1-4 394 (49) 42 (48) 177 (44) 5-10 196 (24) 11 (13) 98 (24) 11-100 169 (21) 20 (23) 92 (23) 1100 44 (5) 13 (15) a 34 (8) [log-rank test]). P ! .001 B, Probability of not dying of AIDS by HCV status for these 1307 women. The number of women who died an AIDS-related death was 162: 97 HCVnegative women; 7 HCV-positive nonviremic women; and 11, 12, 13, and 22 HCV-positive viremic women with RNA levels of р983,000, 983,001-2,395,000, 2,395,001-3,980,000, and 13,980,000 IU/mL, respectively ( [log-rank test]). C, Probability of remaining AIDS-free by HCV status P p .03 among 881 women who never had a CD4 T cell count of !200 cells/mL. Of these 881 women, the number of women who developed AIDS-defining conditions was 264: 145 HCV-negative women; 24 HCV-positive nonviremic women; and 25, 23, 27, and 20 HCV-positive viremic women with RNA levels of р983,000, 983,001-2,395,000, 2,395,001-3,980,000, and 13 
DISCUSSION
HIV-positive patients with chronic active or reactivating viral coinfections (eg, cytomegalovirus or herpes simplex virus coinfections) have higher plasma HIV RNA levels, lower T cell counts, and greater progression to AIDS compared with HIVpositive patients without evidence of infection/reactivation [31, 32] . For HCV coinfection, however, there have been conflicting reports [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Consequently, our findings from this large cohort study, which included 1307 women, are notable. First, women with high baseline HCV RNA levels have an increased risk of AIDS, independent of CD4 cell count and HIV RNA level. Second, there was an almost 2-fold increased probability of developing AIDS for HCV-positive women compared with HCV-negative women who never had a CD4 cell count of !200 cells/mL and for women who remained ART naive. Third, HCV coinfection was associated with increased CD8 activation. Finally, our most important finding was the statistically significant association between the level of activated CD8 T cells and incident AIDS among HCV-positive viremic women. HCV-positive viremic women with 143% activated CD8 T cells had an almost 3-fold increased risk of AIDS-defining conditions and/ NOTE. Generalized estimating equations model: dependent variable, immune activation marker; independent variables, baseline hepatitis C virus (HCV) status, CD4 T cell count, human immunodeficiency virus (HIV) RNA level, age, injection drug use, and antiretroviral therapy (all but baseline HCV status and race were time varying). DR, HLA-DR; HAART, highly active antiretroviral therapy; NA, not applicable; SEM, standard error of the mean. a The multivariate model included factors that were statistically significantly associated with both baseline HCV status and T cell activation. b P value for trend among HCV-positive women. c The P values for the African American, Hispanic, and other race categories are compared with those for the white race category.
or AIDS-related deaths compared with HCV-positive viremic women with !26% activated CD8 T cells. This was not found for HCV-negative women. In contrast, high levels of CD4 activation similarly predicted AIDS in both groups of women. These data suggest that the increased risk of HIV disease progression among HCV-coinfected women with high levels of CD8 activation may be due to immune dysfunction. Importantly, we also showed that women with high percentages of CD8 + CD38 Ϫ DR + and CD4
cells had a 50%-70% decreased AIDS risk, which suggests better immunity among this group of women. To our knowledge, the Swiss HIV Cohort Study [17] was Table 4 .
Multivariate Associations between Immune Activation Markers and Incident AIDS among HIV-Infected Women
Immune activation marker, model Hazard ratio and 95% confidence interval for tertile relative to tertile 1.
the first large study to demonstrate that HCV accelerated HIV disease independent of injection drug use. Other studies found no effect of HCV on HIV disease progression, although recent studies have reported increased risk [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Our study, in which only 10%-20% of the participants were active injection drug users during follow-up, demonstrates an increased risk of an AIDS-defining condition with increasing HCV RNA level. Furthermore, our study assessed outcome from the time of study entry to the time of an AIDS-defining condition adjusting for ART in time-dependent Cox models, whereas some studies limited outcome from initiation of highly active ART or excluded women with CD4 cell counts of !200 cells/mL at baseline, neither of which was done in our study. Although the effect of HCV genotype on immune activation is unknown, most women in our study were infected with genotype 1, which is associated with higher HCV RNA levels [33] . In our study, higher HCV RNA levels correlate with higher levels of immune activation. Differences in genotype or in rates of active injection drug use may explain differences between the results of our study and those in previous reports [19] . Immune activation has been closely linked to HIV disease progression [1, 4, 5, [34] [35] [36] , but to our knowledge this association has not previously been reported in the setting of HCV coinfection. Our finding of increased incidence of AIDS-defining conditions in relation to high levels of immune activation suggests that there is impaired T cell function in HCV-positive viremic women that may potentially put them at higher risk of HIV disease progression compared with HCV-negative women.
There are a number of factors that could potentially influence immune activation and in turn pathogenesis of HIV disease, including age, race, gender, injection drugs, use of highly active ART and antibiotic prophylaxis, smoking, alcohol, HCV genotype, and extent of liver damage. We evaluated for each of these in univariate models and then in multivariate models when appropriate.
In vitro studies have shown that CD8 T cells have a lower threshold for activation and proliferation compared with CD4 T cells [37] . Ongoing antigen-driven activation of CD8 T cells ultimately leads to CD8 T cell exhaustion and replicative senescence, which lead to inability to fight opportunistic pathogens [4] . The factors that influence T cell activation among the women included in our study are most likely multifactorial and may be a direct consequence of activation in the liver or may be related to extrahepatic replication of HCV [38] . Alternatively, host-specific factors (eg, cytokines) may drive persistent T cell activation. Furthermore, factors that drive immune activation may increase the available targets for further viral replication. Finally, HCV infection may impair T cell maturation more globally to a more immature primed activated phenotype and also may impair responses to Toll-like receptors, suggesting that both the innate and adaptive arms are affected [24, 39] .
Our study systematically evaluated the association between HCV viremia, immune activation, and AIDS outcome. We determined that (1) HCV viremia is associated with AIDS outcome, independent of injection drug use, HIV RNA level, CD4 cell count, and ART (Table 2) ; (2) HCV viremia is associated with CD4 and CD8 activation, independent of HIV RNA level (Table 3) ; and (3) high levels of CD8 activation are associated with AIDS in HCV-positive viremic women but not in HCVnegative women. Our multivariate models showed that the causal pathway between T cell activation and HIV disease progression cannot be completely explained by HIV or HCV viral load, and other mediators of CD8 activation may be involved in increasing AIDS risk. This may be because substantial immune activation occurs in tissues such as the liver, and viral load may not reflect the extent of the activation. For instance, recently there has been evidence that the gastrointestinal tract is a site for activation of T cells as a result of microbial translocation. Gut-associated T cell depletion may also have a significant effect on HIV pathogenesis [8, [40] [41] [42] . From the intestines, T cells and microbial antigens circulate directly through the liver, where activation may continue. Whether the liver plays a role in amplifying or modulating this activation, especially with prior HCV infection, is unknown, but a recent study found evidence of increased microbial translocation among HCV-positive individuals with cirrhosis [43] . In our study, liver biopsy data were unavailable. However, we did evaluate for liver disease by use of the aspartate to platelet ratio index [30] and found no statistically significant correlation with AIDS risk. Furthermore, we found no association between alcohol use and AIDS outcome. On the other hand, although at the time of AIDS diagnosis there were no statistically significant differences in individual AIDS-defining conditions noted between HCV-negative women and HCV-positive women, HCV viremic women were more likely to report wasting syndrome, bacterial pneumonia, and encephalopathy at the end of followup. This finding suggests that HCV-positive viremic women may be at continued risk for certain AIDS-defining conditions and further supports the importance of treatment in this group. The pathogenesis of these findings may be HCV-related infection of the central nervous system and/or progressive liver disease including cirrhosis. Bacterial pneumonia is increased among HIV-infected individuals, especially injection drug users [44, 45] , and cirrhosis may play a role in some who are coinfected with HCV. However, continued immune activation is also associated with encephalopathy, and some studies have suggested that microbial translocation related to gut-associated immunodeficiency may be a contributing factor [43, [46] [47] [48] . Furthermore, wasting syndrome may be a manifestation of chronic and severe gut-associated immunodeficiency that may be exacerbated by progressive HCV disease and/or alcohol use.
Our study results confirm those of previous studies that the presence of HLA-DR on CD8 T cells without CD38 expression appears to be protective [36, 49] . This is consistent with reports showing that elite controllers have higher percentages of HIV-specific and global CD8 + CD38
Ϫ DR + T cells [49] . CD8 + CD38 Ϫ DR + T cells appear to have high proliferative capacity and cytotoxic activity upon antigenic stimulation. Our study results suggest further research is needed to better understand the path of CD8 activation, especially the protective effect of HLA-DR expression.
Although our study is unique, it has limitations. We did not have information on the timing of HIV or HCV infection. Furthermore, HCV-positive women and HCV-negative women may be different because of differing routes of HIV infection (injection drug use vs sexual). Immune activation markers were measured for only a subset of the study population [7, 24, 25] , and not all phenotypic markers were measured at the same time. Nevertheless, our results confirmed previous observations by other investigators [1, 6, 36] . Finally, we evaluated HCV RNA levels only at baseline because not all women underwent multiple measures. We assumed that HCV RNA levels would not change substantially in women who were not treated for HCV infection, on the basis of published studies that found that even with initiation and discontinuation of highly active ART there is only a 0.43-0.59 log change in HCV viral load [50] ; such small changes would not affect our findings.
In conclusion, our study demonstrates that HIV-coinfected HCV-positive viremic women are at increased risk for AIDSdefining conditions compared with HCV-negative women, possibly because of high levels of activation of T cells, especially CD8 T cells, which indicates increased immune dysregulation in this population of women. Lower levels of activation of both CD8 and CD4 T cells and activation of CD8 T cells expressing only HLA-DR is protective against AIDS. Further study is needed to understand better the pathogenesis of T cell activation, especially of CD8 T cells in relation to HIV disease. HCV-positive viremic women may benefit from treatment of HIV and HCV infection to prevent significant immunologic changes and improve long-term outcome. Assessing CD4 and CD8 T cell activation could help clinicians evaluate their patients' risk of developing AIDS.
